TAS-102

Identification

Name
TAS-102
Accession Number
DB08937
Description

TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.

Type
Small Molecule
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
733030-01-8
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M: A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004 Sep;25(3):571-8. [PubMed:15289858]
  2. Link [Link]
PubChem Substance
347910389
Wikipedia
TAS-102

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentRefractory Metastatic Gastric Cancer1
3WithdrawnTreatmentCarcinoma NOS / Metastatic Colorectal Cancer (MCRC)1
2Active Not RecruitingTreatmentCholangiocarcinomas / Stage III Gallbladder Cancer AJCC V7 / Stage IIIA Gallbladder Cancer AJCC v7 / Stage IIIB Gallbladder Cancer AJCC v7 / Stage IV Gallbladder Cancer AJCC v7 / Stage IVA Gallbladder Cancer AJCC v7 / Stage IVB Gallbladder Cancer AJCC v71
2Active Not RecruitingTreatmentSquamous Cell Lung Carcinoma1
2CompletedTreatmentRefractory, metastatic Colorectal cancer1
2RecruitingTreatmentAdvanced Bile Duct Carcinoma / Advanced Gallbladder Carcinoma / Refractory Bile Duct Carcinoma / Refractory Gallbladder Carcinoma / Stage III Distal Bile Duct Cancer AJCC v8 / Stage III Gallbladder Cancer AJCC v8 / Stage III Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIA Distal Bile Duct Cancer AJCC v8 / Stage IIIA Gallbladder Cancer AJCC v8 / Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIB Distal Bile Duct Cancer AJCC v8 / Stage IIIB Gallbladder Cancer AJCC v8 / Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8 / Stage IV Distal Bile Duct Cancer AJCC v8 / Stage IV Gallbladder Cancer AJCC v8 / Stage IV Intrahepatic Bile Duct Cancer AJCC v8 / Stage IVA Gallbladder Cancer AJCC v8 / Stage IVB Gallbladder Cancer AJCC v81
2RecruitingTreatmentAdvanced Colorectal Carcinoma / Metastatic Colon Adenocarcinoma / Metastatic Rectal Adenocarcinoma / Recurrent Colon Adenocarcinoma / Recurrent Colorectal Adenocarcinoma / Recurrent Rectal Adenocarcinoma / Stage III Colon Cancer AJCC v8 / Stage III Colorectal Cancer AJCC v8 / Stage III Rectal Cancer AJCC v8 / Stage IIIA Colon Cancer AJCC v8 / Stage IIIA Colorectal Cancer AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIB Rectal Cancer AJCC v8 / Stage IIIC Colon Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colon Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVA Rectal Cancer AJCC v8 / Stage IVB Colon Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVB Rectal Cancer AJCC v8 / Stage IVC Colon Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Stage IVC Rectal Cancer AJCC v8 / Unresectable Colon Adenocarcinoma / Unresectable Colorectal Carcinoma / Unresectable Rectal Adenocarcinoma1
2RecruitingTreatmentCancer, Bladder1
2RecruitingTreatmentHigh-grade Extra Pulmonary Neuroendocrine Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on March 07, 2014 10:52 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates